FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164686205> ?p ?o ?g. }

• W3164686205 endingPage "948" @default.
• W3164686205 startingPage "948.2" @default.
• W3164686205 abstract "Background: Biological agents (BA), especially TNF inhibitors, are high efficacy options for current therapy for patients (pts) with juvenile idiopathic arthritis (JIA). They are successfully used not only for the arthritis but also for JIA-associated uveitis, however, development of uveitis de novo in pts treated with BA is a well-established paradoxical phenomenon. Objectives: to evaluate the frequency of new onset ( no -) uveitis, occurring under BA therapy in JIA pts, to establish clinical features, which may be associated with development of such effects. Methods: retrospective cohort study involved all JIA pts (1136) who were treated with BA in our clinic from 2004 to 2020. All cases of no -uveitis were collected for the describing of their clinical features in disease onset and course, activity level, JIA category, exposure to Methotrexate (MTX) and BA, presence of ANA, HLA B27. Results: among of 1136 pts treated with different BA we identified 36 (3.3%) pts (19 female/17 male) with no -uveitis under BA. Mostly during etanercept (ETA) therapy (34 cases from 488 ETA courses, 7%), 1/166 - in abatacept (ABA) and 1/372 - in adalimumab (ADA). 30 pts (83%) with no -uveitis developed it on the 1 st line of BA treatment (29 ETA vs 1 ADA). 4pts (11%) developed no -uveitis on 2 nd line (3 ETA vs 1 ABA). 2 pts (6%) on third line (all ETA, both pts had also psoriasis). There are no cases of no -uveitis under other BA. Frequency of no -uveitis was much higher in ETA group. ETA exposure was 26.8 ± 28.8 months (mo). It means there are no “safe” period of therapy from paradoxical phenomenon of no-uveitis. JIA subtypes were as follows: RF-neg polyarthritis 9 (25%), persistent oligoarthritis 3 (8%), extended oligoarthritis 21 (59%), enthesitis-related arthritis (ERA) - 3 (8%). Average age at JIA onset was 4.6 ± 3.9 yrs. 20/36 patients had high laboratory activity (CRP 54 ± 23 mg/l; ESR 41 ± 19 mm/h) and severe arthritis before BA initiation. However most of pts (25/36) achieved 90-100% ACRpedi-response by the uveitis development. 23/36 pts were ANA-positive, 17/36 pts had HLAB27, including 7 pts who had the both features. Uveitis was occurred earlier in ANA plus HLAB27 positive pts (mean exposure - 15.3 mo) than in only ANA-positive or HLAB27-positive pts (27.7 mo and 27.6 mo accordingly). 29/36 (81%) of pts received methotrexate (MTX) in mean dosage 11.5 mg/m 2 /week. There are no differences in time of uveitis development depending of MTX. In all cases of no -uveitis BA was switched. Conclusion: Our study suggested that new onset of uveitis is rare adverse event during BA therapy in JIA. Uveitis can develop despite the excellent effect of therapy on joint manifestation. The most typical development of no -uveitis is under ETA therapy, especially in the predisposed cases (certain variants of JIA, ANF positivity, HLAB27 presence) and in patients with very high disease activity at the time of the start of biological therapy. Disclosure of Interests: Irina Nikishina Speakers bureau: Novartis, MSD, Pfizer, Abbvie, Hofman la Roche, Svetlana Arsenyeva: None declared, Maria Kaleda Speakers bureau: Novartis, Roche, MSD, Olga Kostareva: None declared, Anna Shapovalenko: None declared, Ekaterina Denisova: None declared, Anna Panova: None declared" @default.
• W3164686205 created "2021-06-07" @default.
• W3164686205 creator A5027586074 @default.
• W3164686205 creator A5035138565 @default.
• W3164686205 creator A5053014303 @default.
• W3164686205 creator A5073212216 @default.
• W3164686205 creator A5084479240 @default.
• W3164686205 creator A5088447832 @default.
• W3164686205 creator A5091020794 @default.
• W3164686205 date "2021-05-19" @default.
• W3164686205 modified "2023-09-26" @default.
• W3164686205 title "POS1332 ETANERCEPT-ASSOCIATED NEW ONSET UVEITIS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS UNDER BIOLOGICAL THERAPY: SINGLE CENTER EXPERIENCE" @default.
• W3164686205 doi "https://doi.org/10.1136/annrheumdis-2021-eular.4135" @default.
• W3164686205 hasPublicationYear "2021" @default.
• W3164686205 type Work @default.
• W3164686205 sameAs 3164686205 @default.
• W3164686205 citedByCount "1" @default.
• W3164686205 countsByYear W31646862052021 @default.
• W3164686205 crossrefType "journal-article" @default.
• W3164686205 hasAuthorship W3164686205A5027586074 @default.
• W3164686205 hasAuthorship W3164686205A5035138565 @default.
• W3164686205 hasAuthorship W3164686205A5053014303 @default.
• W3164686205 hasAuthorship W3164686205A5073212216 @default.
• W3164686205 hasAuthorship W3164686205A5084479240 @default.
• W3164686205 hasAuthorship W3164686205A5088447832 @default.
• W3164686205 hasAuthorship W3164686205A5091020794 @default.
• W3164686205 hasBestOaLocation W31646862051 @default.
• W3164686205 hasConcept C126322002 @default.
• W3164686205 hasConcept C16005928 @default.
• W3164686205 hasConcept C203014093 @default.
• W3164686205 hasConcept C2776194053 @default.
• W3164686205 hasConcept C2777077863 @default.
• W3164686205 hasConcept C2777138892 @default.
• W3164686205 hasConcept C2777226972 @default.
• W3164686205 hasConcept C2777575956 @default.
• W3164686205 hasConcept C2779134260 @default.
• W3164686205 hasConcept C2779338263 @default.
• W3164686205 hasConcept C2779605438 @default.
• W3164686205 hasConcept C2780132546 @default.
• W3164686205 hasConcept C2780564577 @default.
• W3164686205 hasConcept C2780653079 @default.
• W3164686205 hasConcept C2781059491 @default.
• W3164686205 hasConcept C2781290027 @default.
• W3164686205 hasConcept C2781301800 @default.
• W3164686205 hasConcept C71924100 @default.
• W3164686205 hasConceptScore W3164686205C126322002 @default.
• W3164686205 hasConceptScore W3164686205C16005928 @default.
• W3164686205 hasConceptScore W3164686205C203014093 @default.
• W3164686205 hasConceptScore W3164686205C2776194053 @default.
• W3164686205 hasConceptScore W3164686205C2777077863 @default.
• W3164686205 hasConceptScore W3164686205C2777138892 @default.
• W3164686205 hasConceptScore W3164686205C2777226972 @default.
• W3164686205 hasConceptScore W3164686205C2777575956 @default.
• W3164686205 hasConceptScore W3164686205C2779134260 @default.
• W3164686205 hasConceptScore W3164686205C2779338263 @default.
• W3164686205 hasConceptScore W3164686205C2779605438 @default.
• W3164686205 hasConceptScore W3164686205C2780132546 @default.
• W3164686205 hasConceptScore W3164686205C2780564577 @default.
• W3164686205 hasConceptScore W3164686205C2780653079 @default.
• W3164686205 hasConceptScore W3164686205C2781059491 @default.
• W3164686205 hasConceptScore W3164686205C2781290027 @default.
• W3164686205 hasConceptScore W3164686205C2781301800 @default.
• W3164686205 hasConceptScore W3164686205C71924100 @default.
• W3164686205 hasIssue "Suppl 1" @default.
• W3164686205 hasLocation W31646862051 @default.
• W3164686205 hasOpenAccess W3164686205 @default.
• W3164686205 hasPrimaryLocation W31646862051 @default.
• W3164686205 hasRelatedWork W2075390633 @default.
• W3164686205 hasRelatedWork W2151699583 @default.
• W3164686205 hasRelatedWork W2318383784 @default.
• W3164686205 hasRelatedWork W2560268971 @default.
• W3164686205 hasRelatedWork W2975923983 @default.
• W3164686205 hasRelatedWork W3034186223 @default.
• W3164686205 hasRelatedWork W3129801091 @default.
• W3164686205 hasRelatedWork W3164686205 @default.
• W3164686205 hasRelatedWork W4226058549 @default.
• W3164686205 hasRelatedWork W4283693936 @default.
• W3164686205 hasVolume "80" @default.
• W3164686205 isParatext "false" @default.
• W3164686205 isRetracted "false" @default.
• W3164686205 magId "3164686205" @default.
• W3164686205 workType "article" @default.